Skip to main content
Erschienen in: Clinical Rheumatology 12/2023

24.07.2023 | ORIGINAL ARTICLE

Retrospective analysis and preliminary laboratory validation of treatment efficacy and blood lipid levels in patients with rheumatoid arthritis

verfasst von: Yuchun Wang, Han Xie, Xuan Huang, Keyuan Chen, Yizhun Zhu, Genhong Yao

Erschienen in: Clinical Rheumatology | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Rheumatoid arthritis is a systemic disease characterized by progressive chronic inflammation resulting in destruction of synovial joints. In addition to joint involvement, abnormal blood lipid indexes have also been found in RA patients. The correlation between various blood lipid indexes and the treatment effects were assessed in patients with rheumatoid arthritis, for the purposes to find a better medication strategy for RA.

Methods

One hundred nineteen rheumatoid arthritis patients were recruited and divided into two groups, 45 patients with significant drug treatment effect and 45 patients with insignificant drug treatment effect through the nearest neighbor matching method in propensity score. The correlation between various blood lipid indexes and drug treatment effect of rheumatoid arthritis patients was analyzed. A mouse model of rheumatoid arthritis was constructed in the laboratory; methotrexate was treated as a positive drug. We observe and record the onset of rheumatoid arthritis in mice, as well as the proportion of immune cells, the expression of inflammatory factors, and the changes in blood lipid profiles was done.

Results

The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), and erythrocyte sedimentation rate (ESR) in rheumatoid arthritis patients were significantly different between the two groups (P < 0.05). There was no significant difference in other indexes between the two groups (P > 0.05). Methotrexate had a good therapeutic effect on CIA model mice, and the levels of TC and HDL-C in the treatment group were higher than those in the model group.

Conclusion

There is a high correlation between the levels of TC and HDL-C in rheumatoid arthritis patients and the effect of drug treatment. In the clinical treatment of rheumatoid arthritis, we should focus on improving the blood lipid indexes such as TC and HDL-C, and explore more targeted individualized administration, so as to achieve better and faster treatment effect in patients with rheumatoid arthritis.
Key Points
• In this research, we found that the TC and HDL-C level in RA patients’ blood is highly related with the therapeutic effect, and a lower level of TC and HDL-C is better for therapeutic effect of RA.
Literatur
3.
Zurück zum Zitat Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD (2010) Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 6:445–451CrossRef Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD (2010) Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 6:445–451CrossRef
4.
Zurück zum Zitat Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A (2021) Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev 20:102776CrossRefPubMed Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A (2021) Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev 20:102776CrossRefPubMed
5.
Zurück zum Zitat Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR (2020) Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 72:31–40CrossRefPubMed Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR (2020) Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 72:31–40CrossRefPubMed
6.
Zurück zum Zitat Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL (2020) Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 6:104–114CrossRefPubMed Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL (2020) Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 6:104–114CrossRefPubMed
7.
Zurück zum Zitat Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB (2015) Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 67:616–625CrossRefPubMedPubMedCentral Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB (2015) Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 67:616–625CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Pierini FS, Botta E, Soriano ER, Martin M, Boero L, Merono T, Saez MS, Lozano Chiappe E, Cerda O, Citera G, Gandino I, Rosa J, Sorroche P, Kontush A, Brites F (2021) Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An Observational Study Rheumatol Ther 8:803–815PubMed Pierini FS, Botta E, Soriano ER, Martin M, Boero L, Merono T, Saez MS, Lozano Chiappe E, Cerda O, Citera G, Gandino I, Rosa J, Sorroche P, Kontush A, Brites F (2021) Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An Observational Study Rheumatol Ther 8:803–815PubMed
9.
Zurück zum Zitat Yoo WH (2004) Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 31:1746–1753PubMed Yoo WH (2004) Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 31:1746–1753PubMed
10.
Zurück zum Zitat Nerurkar L, Siebert S, McInnes IB, Cavanagh J (2019) Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6:164–173CrossRefPubMed Nerurkar L, Siebert S, McInnes IB, Cavanagh J (2019) Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6:164–173CrossRefPubMed
11.
Zurück zum Zitat Buch MH, Eyre S, McGonagle D (2021) Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 17:17–33CrossRefPubMed Buch MH, Eyre S, McGonagle D (2021) Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 17:17–33CrossRefPubMed
12.
Zurück zum Zitat Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gomez-Reino JJ (2015) Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67:117–127CrossRefPubMed Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gomez-Reino JJ (2015) Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67:117–127CrossRefPubMed
13.
Zurück zum Zitat Amezaga Urruela M, Suarez-Almazor ME (2012) Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. Curr Rheumatol Rep 14:428–437CrossRef Amezaga Urruela M, Suarez-Almazor ME (2012) Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. Curr Rheumatol Rep 14:428–437CrossRef
14.
Zurück zum Zitat Robertson J, Peters MJ, McInnes IB, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9:513–523CrossRef Robertson J, Peters MJ, McInnes IB, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9:513–523CrossRef
15.
Zurück zum Zitat Bag-Ozbek A, Giles JT (2015) Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep 15:497CrossRef Bag-Ozbek A, Giles JT (2015) Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep 15:497CrossRef
16.
Zurück zum Zitat Bergstrom U, Jovinge S, Persson J, Jacobsson LTH, Turesson C (2018) Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Curr Ther Res Clin Exp 89:1–6CrossRefPubMed Bergstrom U, Jovinge S, Persson J, Jacobsson LTH, Turesson C (2018) Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Curr Ther Res Clin Exp 89:1–6CrossRefPubMed
17.
Zurück zum Zitat Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, Lavie I, Gazitt T, Zisman D (2019) Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci 20:4633–4644 Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, Lavie I, Gazitt T, Zisman D (2019) Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci 20:4633–4644
18.
Zurück zum Zitat Steiner G, Urowitz MB (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 38:372–381CrossRefPubMed Steiner G, Urowitz MB (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 38:372–381CrossRefPubMed
19.
Zurück zum Zitat Kay J, Upchurch KS (2012) ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 51 Suppl 6:vi5-9 Kay J, Upchurch KS (2012) ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 51 Suppl 6:vi5-9
20.
Zurück zum Zitat van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, Twisk JW, van de Stadt RJ, de Koning MH, Habibuw MR, van der Horst-Bruinsma IE, Dijkmans BA (2007) Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 66:184–188CrossRef van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, Twisk JW, van de Stadt RJ, de Koning MH, Habibuw MR, van der Horst-Bruinsma IE, Dijkmans BA (2007) Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 66:184–188CrossRef
21.
Zurück zum Zitat Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903–911CrossRef Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903–911CrossRef
22.
Zurück zum Zitat Iannello S, Camuto M, Cavaleri A, Fagone S, Belfiore F (2000) Psoriasis complicated with severe mutilating psoriatic osteoarthropathy. Clinical case and review of the literature. Minerva Med 91:191–226PubMed Iannello S, Camuto M, Cavaleri A, Fagone S, Belfiore F (2000) Psoriasis complicated with severe mutilating psoriatic osteoarthropathy. Clinical case and review of the literature. Minerva Med 91:191–226PubMed
23.
Zurück zum Zitat Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B (2005) The patient’s perspective and rheumatoid arthritis disease activity indexes. Rheumatology (Oxford) 44:360–365CrossRef Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B (2005) The patient’s perspective and rheumatoid arthritis disease activity indexes. Rheumatology (Oxford) 44:360–365CrossRef
24.
Zurück zum Zitat Liebold I, Grutzkau A, Gockeritz A, Gerl V, Lindquist R, Feist E, Zanker M, Haupl T, Poddubnyy D, Zernicke J, Smiljanovic B, Alexander T, Burmester GR, Gay S, Stuhlmuller B (2021) Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity. Rheumatology (Oxford) 60:1984–1995CrossRefPubMed Liebold I, Grutzkau A, Gockeritz A, Gerl V, Lindquist R, Feist E, Zanker M, Haupl T, Poddubnyy D, Zernicke J, Smiljanovic B, Alexander T, Burmester GR, Gay S, Stuhlmuller B (2021) Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity. Rheumatology (Oxford) 60:1984–1995CrossRefPubMed
25.
26.
Zurück zum Zitat Jarc E, Petan T (2020) A twist of FATe: lipid droplets and inflammatory lipid mediators. Biochimie 169:69–87CrossRefPubMed Jarc E, Petan T (2020) A twist of FATe: lipid droplets and inflammatory lipid mediators. Biochimie 169:69–87CrossRefPubMed
27.
28.
Zurück zum Zitat Brouwers H, von Hegedus J, Toes R, Kloppenburg M, Ioan-Facsinay A (2015) Lipid mediators of inflammation in rheumatoid arthritis and osteoarthritis. Best Pract Res Clin Rheumatol 29:741–755CrossRefPubMed Brouwers H, von Hegedus J, Toes R, Kloppenburg M, Ioan-Facsinay A (2015) Lipid mediators of inflammation in rheumatoid arthritis and osteoarthritis. Best Pract Res Clin Rheumatol 29:741–755CrossRefPubMed
29.
31.
32.
Zurück zum Zitat Thomas HC, Potter BJ, Sherlock S (1977) Is primary biliary cirrhosis an immune complex disease? Lancet 2:1261–1263CrossRefPubMed Thomas HC, Potter BJ, Sherlock S (1977) Is primary biliary cirrhosis an immune complex disease? Lancet 2:1261–1263CrossRefPubMed
33.
Zurück zum Zitat Williams BD, Pussell BA, Lockwood CM, Cotton C (1979) Defective reticuloendothelial system function in rheumatoid arthritis. Lancet 1:1311–1314CrossRef Williams BD, Pussell BA, Lockwood CM, Cotton C (1979) Defective reticuloendothelial system function in rheumatoid arthritis. Lancet 1:1311–1314CrossRef
34.
Zurück zum Zitat Rossol M, Kaltenhauser S, Scholz R, Hantzschel H, Hauschildt S, Wagner U (2005) The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis. Arthritis Res Ther 7:R1189–R1199CrossRefPubMedPubMedCentral Rossol M, Kaltenhauser S, Scholz R, Hantzschel H, Hauschildt S, Wagner U (2005) The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis. Arthritis Res Ther 7:R1189–R1199CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Naerr GW, Rein P, Saely CH, Drexel H (2016) Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascul Pharmacol 81:22–30CrossRef Naerr GW, Rein P, Saely CH, Drexel H (2016) Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascul Pharmacol 81:22–30CrossRef
36.
Zurück zum Zitat Kardassis D, Mosialou I, Kanaki M, Tiniakou I, Thymiakou E (2014) Metabolism of HDL and its regulation. Curr Med Chem 21:2864–2880CrossRefPubMed Kardassis D, Mosialou I, Kanaki M, Tiniakou I, Thymiakou E (2014) Metabolism of HDL and its regulation. Curr Med Chem 21:2864–2880CrossRefPubMed
37.
Zurück zum Zitat Behl T, Kaur I, Sehgal A, Zengin G, Brisc C, Brisc MC, Munteanu MA, Nistor-Cseppento DC, Bungau S (2020) The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. Int J Mol Sci 21:9505–9532 Behl T, Kaur I, Sehgal A, Zengin G, Brisc C, Brisc MC, Munteanu MA, Nistor-Cseppento DC, Bungau S (2020) The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. Int J Mol Sci 21:9505–9532
38.
Zurück zum Zitat Su X, Zhang G, Cheng Y, Wang B (2021) New insights into the emerging effects of inflammatory response on HDL particles structure and function. Mol Biol Rep 48:5723–5733CrossRef Su X, Zhang G, Cheng Y, Wang B (2021) New insights into the emerging effects of inflammatory response on HDL particles structure and function. Mol Biol Rep 48:5723–5733CrossRef
39.
Zurück zum Zitat Ahmed S, Jacob B, Carsons SE, De Leon J, Reiss AB (2021) Treatment of cardiovascular disease in rheumatoid arthritis: a complex challenge with increased atherosclerotic risk. Pharmaceuticals (Basel) 15:11 Ahmed S, Jacob B, Carsons SE, De Leon J, Reiss AB (2021) Treatment of cardiovascular disease in rheumatoid arthritis: a complex challenge with increased atherosclerotic risk. Pharmaceuticals (Basel) 15:11
40.
Zurück zum Zitat Yiu JHC, Chan KS, Cheung J, Li J, Liu Y, Wang Y, Fung WWL, Cai J, Cheung SWM, Dorweiler B, Wan EYF, Tso P, Xu A, Woo CW (2020) Gut microbiota-associated activation of TLR5 induces apolipoprotein A1 production in the liver. Circ Res 127:1236–1252CrossRefPubMedPubMedCentral Yiu JHC, Chan KS, Cheung J, Li J, Liu Y, Wang Y, Fung WWL, Cai J, Cheung SWM, Dorweiler B, Wan EYF, Tso P, Xu A, Woo CW (2020) Gut microbiota-associated activation of TLR5 induces apolipoprotein A1 production in the liver. Circ Res 127:1236–1252CrossRefPubMedPubMedCentral
Metadaten
Titel
Retrospective analysis and preliminary laboratory validation of treatment efficacy and blood lipid levels in patients with rheumatoid arthritis
verfasst von
Yuchun Wang
Han Xie
Xuan Huang
Keyuan Chen
Yizhun Zhu
Genhong Yao
Publikationsdatum
24.07.2023
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 12/2023
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-023-06683-9

Weitere Artikel der Ausgabe 12/2023

Clinical Rheumatology 12/2023 Zur Ausgabe

LETTERS OF BIOMEDICAL AND CLINICAL RESEARCH

Exploring the patient experience in polymyalgia rheumatica

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.